Skip to content

Impax Laboratories, LLC

Delisted

CIK 1003642fmd_194YZCWNHGBME1P9TCT5KS8M3EManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2009 to Mar 31, 2018, 34 periods

Latest annual · FY2017

Millions
Total revenues
776
Gross profit
144
Operating income
(403)
Net income
(469)
Free cash flow
57

Latest quarter · Q1 FY2018

Millions
Total revenues
142
Gross profit
30
Operating income
(125)
Net income
(131)
Free cash flow
(89)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2014 to FY2017
+9.2%
Revenue, 5 yearsFY2012 to FY2017
+5.9%
Net income, 5 yearsFY2012 to FY2017
n/m

Impax Laboratories, LLC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2017FY2016ChangeSource
Revenue$775.8 million$824.4 million-5.9%10-K 2018-03-01 · proof
Gross profit$143.8 million-$151.1 million10-K 2018-03-01 · proof
Operating income-$402.7 million-$494.2 million10-K 2018-03-01 · proof
Net income-$469.3 million-$472 million10-K 2018-03-01 · proof
Cash from operating activities$84.2 million$83.9 million+0.4%10-K 2018-03-01 · proof
Free cash flow$57.5 million$34.4 million+66.8%10-K 2018-03-01 · proof
Total assets$1.4 billion$1.8 billion-25.9%10-K 2018-03-01 · proof
Total liabilities$1.2 billion$1.2 billion-2.9%10-K 2018-03-01 · proof
Cash and cash equivalents$181.8 million$180.1 million+0.9%10-K 2018-03-01 · proof
Total debt$787.4 million$831.3 million-5.3%10-K 2018-03-01 · proof
What was Impax Laboratories, LLC's revenue in fiscal 2017?
Impax Laboratories, LLC reported revenue of $775.8 million for fiscal 2017 (the year ended Dec 31, 2017), against $824.4 million the year before (-5.9%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Impax Laboratories, LLC's gross profit in fiscal 2017?
Impax Laboratories, LLC reported gross profit of $143.8 million for fiscal 2017 (the year ended Dec 31, 2017), against -$151.1 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Impax Laboratories, LLC's operating income in fiscal 2017?
Impax Laboratories, LLC reported operating income of -$402.7 million for fiscal 2017 (the year ended Dec 31, 2017), against -$494.2 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Impax Laboratories, LLC's net income in fiscal 2017?
Impax Laboratories, LLC reported net income of -$469.3 million for fiscal 2017 (the year ended Dec 31, 2017), against -$472 million the year before. Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Impax Laboratories, LLC's cash from operating activities in fiscal 2017?
Impax Laboratories, LLC reported cash from operating activities of $84.2 million for fiscal 2017 (the year ended Dec 31, 2017), against $83.9 million the year before (+0.4%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What was Impax Laboratories, LLC's free cash flow in fiscal 2017?
Impax Laboratories, LLC reported free cash flow of $57.5 million for fiscal 2017 (the year ended Dec 31, 2017), against $34.4 million the year before (+66.8%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What are Impax Laboratories, LLC's total assets?
As of Dec 31, 2017, Impax Laboratories, LLC reported total assets of $1.4 billion, against $1.8 billion a year earlier (-25.9%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What are Impax Laboratories, LLC's total liabilities?
As of Dec 31, 2017, Impax Laboratories, LLC reported total liabilities of $1.2 billion, against $1.2 billion a year earlier (-2.9%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What are Impax Laboratories, LLC's cash and cash equivalents?
As of Dec 31, 2017, Impax Laboratories, LLC reported cash and cash equivalents of $181.8 million, against $180.1 million a year earlier (+0.9%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC
What is Impax Laboratories, LLC's total debt?
As of Dec 31, 2017, Impax Laboratories, LLC reported total debt of $787.4 million, against $831.3 million a year earlier (-5.3%). Source: the 10-K filed with the SEC on Mar 1, 2018. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1003642&period_type=annual&limit=5"

Information only, not investment advice.